Recent developments include the announcement of 2025 financial results and a corporate update, a strategic update in early March 2026, and an exclusive distribution agreement for Macrilen in select Asian markets in late 2025.

• COSCIENS reported its fourth quarter and full year 2025 financial results, highlighting revenue of $7.5 million and a net loss of $10.4 million, and provided a corporate update including the wind-down of its biopharmaceutical business [N1][S1].
• The company announced a strategic update on March 5, 2026, detailing the decision to cease funding its German subsidiaries and the insolvency filings of these entities, aiming to reduce operating expenses and extend cash resources [N2][S1].
• COSCIENS entered an exclusive distribution agreement with Wuzhou Drug International for Macrilen® in the Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore, reflecting ongoing commercial activities despite the biopharmaceutical wind-down [N3][S1].

COSCIENS leverages proprietary technologies to produce innovative natural active ingredients with applications across multiple industries, including personal care, cosmetics, and health. The PGX Technology platform offers potential for novel product development with environmental benefits and enhanced product performance. The company’s strategic focus on cost reduction, including exiting loss-making biopharmaceutical operations and plans to suspend SEC reporting, may improve financial sustainability. Ongoing collaborations to scale PGX Technology and exploration of new product categories could support future commercial opportunities. The established distribution network and diversified product portfolio in active ingredients provide a foundation for growth [S1][N1][N2][N3].

The company faces significant challenges including the insolvency of its German subsidiaries and the wind-down of its biopharmaceutical business following unsuccessful clinical trials. The loss of rights to Macrilen and exit from this segment reduces revenue diversity and may impact long-term prospects. Commercialization of PGX Technology remains uncertain, with no current revenue from this platform and reliance on partnerships and licensing. Financial losses and negative cash flows persist, with liquidity dependent on cost-saving measures and operational adjustments. Market competition, regulatory risks, and the ability to protect intellectual property add further uncertainty. The company’s plan to suspend SEC reporting may reduce transparency for investors [S1][N1][N2][N3].

COSCIENS’ moat is based on its proprietary extraction and processing technologies, including Ethanol Fractionation Processes and the patented PGX Technology, which enable the production of high-value natural active ingredients with unique properties. The PGX Technology’s ability to create novel biocomposites and aerogels using green solvents and mild conditions differentiates the company’s product offerings. Additionally, the company’s established distribution networks in personal care, cosmetic, and health industries provide market access. However, the recent wind-down of the biopharmaceutical segment and ongoing commercialization challenges for PGX Technology indicate that the moat is primarily technology-driven and dependent on successful market adoption and partnerships.

• Biopharmaceutical Business Wind-Down: The insolvency filings of German subsidiaries and surrender of rights to Macrilen result in loss of a revenue-generating segment and potential legal and accounting implications.
• Commercialization of PGX Technology: Uncertainty exists regarding the company’s ability to successfully commercialize PGX Technology and generate revenue from this platform.
• Financial Performance and Liquidity: The company has reported net losses and negative cash flows, with liquidity reliant on cost-saving measures and operational adjustments.
• Regulatory and Market Risks: Risks include regulatory approvals, intellectual property protection, market competition, and potential impacts of tariffs and trade barriers.
• Reporting and Transparency: Plans to suspend SEC reporting obligations may reduce transparency and affect investor confidence.

• COSCIENS Biopharma Inc. is a life science company focused on developing and commercializing natural, plant-based active ingredients derived from oats and other renewable plant resources using proprietary manufacturing and extraction technologies [S1].
• The company’s primary active ingredient business includes products such as beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, and oat peptides marketed to personal care, cosmetic, human, and animal health industries primarily through distribution partners and direct sales [S1].
• A small portion of revenues comes from veterinary therapeutic products marketed in Asia, including oat shampoo, ear cleanser, and dermal complex/conditioner [S1].
• COSCIENS has proprietary technologies including Ethanol Fractionation Processes (EFP) and licensed Pressurized Gas eXpanded (PGX) Technology for extraction and processing of bioactives [S1].
• PGX Technology is patented and allows purification, micronization, drying, and combination of biopolymers into porous materials using CO2 and food-grade ethanol at mild temperatures, with applications in functional foods, nutraceuticals, cosmeceuticals, and pharmaceuticals [S1].
• The company is accelerating development and commercialization of PGX Technology, including collaborations with Austria-based NATEX Prozesstechnologie GesmbH to scale up production at facilities in Edmonton and Austria [S1].
• COSCIENS historically operated a biopharmaceutical business through German subsidiaries focused on Macrilen® (macimorelin), an FDA and EMA approved oral test for adult growth hormone deficiency diagnosis, but this segment has operated at a loss and is being wound down following disappointing Phase 3 pediatric trial results and insolvency filings of the German subsidiaries in March 2026 [S1].
• The company anticipates surrendering rights to Macrilen and expects to reduce operating expenses by approximately $1.9 million annually by exiting the biopharmaceutical business [S1].
• COSCIENS reported full year 2025 revenue of $7.5 million and a net loss of $10.4 million, with cash and cash equivalents of $7.3 million as of December 31, 2025 [S1].
• Liquidity ratios as of December 31, 2025, include a current ratio of 3.18 and a cash ratio of 2.02, indicating sufficient short-term liquidity [S1].
• The company’s marketing strategy focuses on selling through distribution networks rather than direct sales, resulting in negligible sales and marketing expenses [S1].
• COSCIENS voluntarily delisted from the Nasdaq Capital Market in September 2025 and plans to suspend SEC reporting obligations under the Exchange Act as part of cost-saving measures [S1].
• The company’s common shares are listed on the Toronto Stock Exchange under the symbol 'CSCI' and on the OTC Market under 'CSCI.F' [S1].
• COSCIENS reported quarterly revenues and net losses fluctuating due to timing of shipments, product mix, and non-recurring items, with a decrease in pharmaceutical revenue following the pediatric trial setback [S1].
• The company has implemented enhanced financial controls and remediation measures, concluding that prior material weaknesses were remediated as of December 31, 2025 [S1].
• COSCIENS has outstanding common shares, stock options, deferred share units, and warrants, with approximately 3.18 million common shares issued as of March 24, 2026 [S1].
• The company’s active ingredients business has shown growth in revenue over recent years, with gross margin improvements, though pharmaceutical revenues have declined due to strategic changes [S1].
• COSCIENS continues to explore new product applications and categories within natural health care products and technologies [S1].
• The company’s financial disclosures emphasize risks including the ability to commercialize PGX Technology, securing strategic partners, and managing liquidity and capital resources [S1].
• Recent news includes the 2025 financial results and corporate update (March 25, 2026), a strategic update (March 5, 2026), and an exclusive distribution agreement for Macrilen in certain Asian markets (December 1, 2025) [N1][N2][N3].